The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / GI Side Effects Leading Reason for Bisphosphonate Nonadherence

GI Side Effects Leading Reason for Bisphosphonate Nonadherence

July 6, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Gastrointestinal side effects are the most common reason osteoporotic women cite for nonadherence to oral bisphosphonate therapy, according to a new survey.

You Might Also Like
  • Did Reports of Side Effects Contribute to Drop in Bone Drug Use?
  • Some Serious Drug Side Effects Not Reported to FDA Within 15 days
  • FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain

“Our findings highlight the importance of low tolerability to nonadherence with osteoporosis therapy and underlines patients’ poor awareness and suboptimal physicians’ involvement in conveying the importance of this therapy,” Dr. Inbal Goldshtein of Maccabi Healthcare Services in Tel Aviv and colleagues state in their report, published on online June 21 in Advances in Therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although bisphosphonates reduce fracture risk in women with osteoporosis, adherence to and persistence with the medications is poor, the researchers write. Several new treatment options, as well as “rare, but alarming” side effects, such as osteonecrosis of the jaw and atypical femur fractures, “have influenced both physicians and patients, and may cause intentional non-adherence with the initially prescribed medication,” they add.

To better understand factors involved in nonadherence or choices to switch treatment, the researchers conducted a survey of 493 women (mean age 66) newly prescribed risedronate or alendronate in 2010–2012 who were either nonadherent (medication possession ratio less than 70%) or changed to a different therapy within a year.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Forty percent stopped taking any anti-osteoporotic treatment, 9% continued on the initial therapy and 51% switched to a different therapy. Among those who discontinued or switched therapy, 40% cited heartburn, acid reflux or other gastrointestinal side effects and 26.7% cited physician recommendation. Patients who discontinued therapy completely most commonly cited side effects (26.9%) and physician recommendation (20%), while 14% cited perceived low importance and 3% cited medication cost.

“Our findings mainly emphasize the need for new medications with a better tolerability profile, and the physician’s unfulfilled role in conveying the benefits of therapy,” Dr. Goldshtein and colleagues write.

“Physicians should further experiment with the various potential strategies to promote adherence, including patients’ education regarding the necessity, expected effect, and duration of treatment, as well as patients’ involvement in choosing the preferred medication regimen,” they suggest.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The authors were unavailable for comment. Merck & Co., which makes alendronate, funded the study and employed one of the coauthors.

Filed Under: Conditions Tagged With: adherence, bisphosphonates, gastrointestinal, Osteoporosis, side effect, Women

You Might Also Like:
  • Did Reports of Side Effects Contribute to Drop in Bone Drug Use?
  • Some Serious Drug Side Effects Not Reported to FDA Within 15 days
  • FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain
  • New Bisphosphonate Therapy Recommendations for Postmenopausal Osteoporosis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.